For Sun Pharma, its investment in speciality business is paying off, as it is becoming a driver of growth for the company’s US business. Cipla’s ‘One India’ strategy, focusing on branded prescription, trade generics and consumer health brands, is leading to continued core portfolio momentum across businesses.
Top 10 PSU performers in CY24. Here’s how much they have returned
As we are at the fag end of 2024, a look back at the performance of PSU stocks shows BSE PSU index delivering nearly 29%